Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 112


HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.

Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA.

J Immunol. 2014 May 1;192(9):4164-73. doi: 10.4049/jimmunol.1303118. Epub 2014 Mar 28.


A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.

Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, Vandenbark AA, Alkayed NJ, Offner H.

Metab Brain Dis. 2014 Mar;29(1):37-45. Erratum in: Metab Brain Dis. 2014 Sep;29(3):885.


HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.

Benedek G, Meza-Romero R, Jordan K, Keenlyside L, Offner H, Vandenbark AA.

J Neuroinflammation. 2015 Jun 24;12:123. doi: 10.1186/s12974-015-0342-4.


Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.

Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows GG, Bourdette D, Offner H, Bucala R, Vandenbark AA.

Eur J Immunol. 2013 May;43(5):1309-21. doi: 10.1002/eji.201243162. Epub 2013 Apr 10.


A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.

Vandenbark AA, Meza-Romero R, Benedek G, Andrew S, Huan J, Chou YK, Buenafe AC, Dahan R, Reiter Y, Mooney JL, Offner H, Burrows GG.

J Autoimmun. 2013 Feb;40:96-110. doi: 10.1016/j.jaut.2012.08.004. Epub 2012 Sep 29.


Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase.

Fan H, Hall P, Santos LL, Gregory JL, Fingerle-Rowson G, Bucala R, Morand EF, Hickey MJ.

J Immunol. 2011 Apr 15;186(8):4915-24. doi: 10.4049/jimmunol.1003713. Epub 2011 Mar 16.


MIF signal transduction initiated by binding to CD74.

Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R.

J Exp Med. 2003 Jun 2;197(11):1467-76.


Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair.

Marsh LM, Cakarova L, Kwapiszewska G, von Wulffen W, Herold S, Seeger W, Lohmeyer J.

Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L442-52. doi: 10.1152/ajplung.00525.2007. Epub 2009 Jan 9.


The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.

Frölich D, Blassfeld D, Reiter K, Giesecke C, Daridon C, Mei HE, Burmester GR, Goldenberg DM, Salama A, Dörner T.

Arthritis Res Ther. 2012 Mar 9;14(2):R54. doi: 10.1186/ar3767.


CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.

Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH, Wang ZH, Shen LS, Cui L.

World J Gastroenterol. 2012 May 14;18(18):2253-61. doi: 10.3748/wjg.v18.i18.2253.


Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74.

Lue H, Dewor M, Leng L, Bucala R, Bernhagen J.

Cell Signal. 2011 Jan;23(1):135-44. doi: 10.1016/j.cellsig.2010.08.013. Epub 2010 Aug 31.


Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF.

Schwartz V, Krüttgen A, Weis J, Weber C, Ostendorf T, Lue H, Bernhagen J.

Eur J Cell Biol. 2012 Jun-Jul;91(6-7):435-49. doi: 10.1016/j.ejcb.2011.08.006. Epub 2011 Oct 19.


Migration inhibitory factor enhances inflammation via CD74 in cartilage end plates with Modic type 1 changes on MRI.

Xiong C, Huang B, Cun Y, Aghdasi BG, Zhou Y.

Clin Orthop Relat Res. 2014 Jun;472(6):1943-54. doi: 10.1007/s11999-014-3508-y. Epub 2014 Feb 26.


Macrophage migration inhibitory factor inhibits the migration of cartilage end plate-derived stem cells by reacting with CD74.

Xiong CJ, Huang B, Zhou Y, Cun YP, Liu LT, Wang J, Li CQ, Pan Y, Wang H.

PLoS One. 2012;7(8):e43984. doi: 10.1371/journal.pone.0043984. Epub 2012 Aug 27. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/a5edef40-e46d-4810-9008-dbda429ccc2c.


CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex.

Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R.

Immunity. 2006 Oct;25(4):595-606.


MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple.

Sanchez-Niño MD, Sanz AB, Ruiz-Andres O, Poveda J, Izquierdo MC, Selgas R, Egido J, Ortiz A.

Cytokine Growth Factor Rev. 2013 Feb;24(1):23-40. doi: 10.1016/j.cytogfr.2012.08.001. Epub 2012 Sep 7. Review.


Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer.

McClelland M, Zhao L, Carskadon S, Arenberg D.

Am J Pathol. 2009 Feb;174(2):638-46. doi: 10.2353/ajpath.2009.080463. Epub 2009 Jan 8.


Upregulation of macrophage migration inhibitory factor (MIF) and CD74, receptor for MIF, in rat bladder during persistent cyclophosphamide-induced inflammation.

Vera PL, Wang X, Meyer-Siegler KL.

Exp Biol Med (Maywood). 2008 May;233(5):620-6. doi: 10.3181/0709-RM-240. Epub 2008 Mar 28.


MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations.

Fan C, Rajasekaran D, Syed MA, Leng L, Loria JP, Bhandari V, Bucala R, Lolis EJ.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):10994-9. doi: 10.1073/pnas.1221817110. Epub 2013 Jun 17.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk